Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine

Starting soon

Conditions studied: Hydroxychloroquine Retinopathy

In brief

This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.

Key facts

Study ID

NCT07409740

Run by

Sohag University

People needed

90

Starts

2026-02-01

Expected to finish

2026-09-01

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults (≥18 years old) with documented HCQ therapy for ≥1 year.
• Stable systemic disease under medical supervision.

You may not qualify if…

• -patients with media opacity.
• Any pre-existing retinal or optic nerve disease (e.g., diabetic retinopathy, AMD, myopic degeneration).
• History of intraocular surgery or trauma.
• Uncontrolled systemic vascular diseases (e.g., hypertension)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.